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Purpose: Ankle osteoarthritis (OA) causes significant pain and debilitation; yet, its underly-
ing mechanisms remain unclear. Clinically, hyaluronic acid (HA) is widely used to treat OA. 
The present study aimed to investigate the roles of HA in pain-related behavior, joint function, 
swelling, and pathological changes in cartilage in a rat model of monoiodoacetate (MIA)-
induced ankle OA.
Materials and methods: Male Sprague Dawley rats were assigned to three experimental 
groups as follows: 1) MIA rats injected with 1 mg MIA in the right tibiotarsal joint for two 
consecutive days; 2) sham rats injected with saline instead of MIA; and 3) MIA-HA rats injected 
with HA in the tibiotarsal joint at 7, 14, and 21 days after MIA injection. Joint swelling, range 
of motion (ROM), and pain-related behavior were evaluated 1 day before and on the 7th, 14th, 
21st, and 28th day after MIA or saline injection. Pathological changes in the ankle joint were 
assessed 28 days after MIA or saline injection.
Results: No significant difference in the degree of ankle swelling or ROM reduction was 
observed between MIA rats and MIA-HA rats. However, compared with those in MIA rats, 
mechanical and thermal hypersensitivity was significantly reduced and stride length signifi-
cantly improved in MIA-HA rats. Histologic analysis revealed that cartilage degeneration was 
significantly suppressed in MIA-HA rats compared with that in MIA rats, reflecting the chon-
droprotective effects of HA.
Conclusion: HA improved pain-related behavior and stride length and suppressed MIA-induced 
cartilage degeneration. HA may thus inhibit OA progression and suppress peripheral and/or 
central sensitization.
Keywords: ankle osteoarthritis, monoiodoacetate, osteoarthritis pain, hyaluronic acid
Introduction
Osteoarthritis (OA) is one of the most prevalent and debilitating joint diseases and is 
associated with reduced quality of life and increased health care costs. OA occurrence is 
attributed to cartilage degeneration, fibrillation, erosion, and osteophyte formation and 
is characterized by chronic pain and loss of joint function in the majority of patients.1 
While the prevalence of knee OA is ~15%–20% in the adult population, ankle OA 
accounts for ~1% of all cases.2,3 Ankle OA tends to occur in older adult populations 
and displays gradual progression; however, patients with ankle OA tend to be younger 
than patients with hip OA and also experience longstanding chronic pain that affects 
their quality of life.4 Further, with increases in the aging population and sports-related 
injuries, the incidence of ankle OA has been increasing.5 The progression to end-stage 
ankle OA has been reported to be ~10–20 years after the initial injury and tends to 
occur in the middle age among most patients.6 Therefore, we should not overlook the 
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burden and the socioeconomic impact of ankle OA.7 Cur-
rently available medical therapies for OA, which include 
traditional analgesics and non-steroidal anti-inflammatory 
drugs (NSAIDs), are ineffective in altering or slowing disease 
progression, but rather alleviate symptoms by reducing pain 
and improving joint mobility. Further, their chronic use has 
been restricted by their deleterious side effects, and surgical 
interventions such as total ankle replacement and arthrodesis 
are eventually required.8,9
In 1997, the US Food and Drug Administration approved 
intra-articular injections of hyaluronic acid (HA) for the treat-
ment of OA.9 Intra-articular HA injections can restore visco-
elasticity by replacing the dysfunctional synovial fluid, which, 
due to the modulation of early inflammatory responses, might 
also exert an analgesic effect on the area.10 HA protects col-
lagen fibrils, cells of the articular surface, synovial tissue, 
capsule, and ligament from mechanical damage. Moreover, 
intra-articular HA knee injections have been shown to have 
a chondroprotective effect in an early knee OA rat model.11 
HA has been widely used in the management of knee OA, and 
the efficacy of this treatment has been confirmed in several 
meta-analyses.9,12–14
In a rat knee OA model, the subchondral bone was found 
to be associated with inflammatory pain and expression of 
pain-related receptors.15 Although OA pain may be correlated 
with peripheral and central sensitization, the mechanisms 
involved in the pain and pathophysiology remain unclear.16 
There have been no fundamental studies investigating the 
antinociceptive effect of intra-articular HA injection in 
ankle OA.
The aging-based model of ankle OA has the distinct 
disadvantage of prolonged delay and is associated with 
slight cartilage denaturation. The surgically induced model 
of ankle OA is created by cutting ligaments around the ankle 
joint;17 however, differences in surgical expertise can affect 
the degree of cartilage denaturation. The ankle fracture 
model also relies on experimental skill.18 Consequently, 
these models have reproducibility issues. We have previously 
reported the utility of the rat model of monoiodoacetate 
(MIA)-induced ankle OA, which can be easily reproduced.19
The present study aimed to evaluate the efficacy of intra-
articular ankle injection of HA, a previously unreported 
strategy, in a rat model of MIA-induced ankle OA.
Materials and methods
hyaluronic acid
We used ARTZ-Dispo HA (weight-average molecular weight 
[MW], 60–120 kDa; viscosity-average MW, 1,650 kDa; 
Seikagaku, Tokyo, Japan).
animal preparation and intra-articular 
injection
All experimental procedures in this study were performed 
according to the Ethical Guidelines of the International 
Association for the Study of Pain and were approved by the 
Animal Care and Use Committee of Sapporo Medical Uni-
versity School of Medicine (Sapporo, Japan). Efforts were 
made to minimize the number of animals used.
We used 60 male Sprague Dawley rats (3 weeks old; 
body weight, 46–58 g). The rats were assigned to three 
experimental groups of 20 rats each (including 15 rats for 
behavioral study and 5 rats for pathological study). Rats in 
the MIA group were injected with MIA (1 mg/30 µL) in the 
tibiotarsal joint of the right hind paw for two consecutive 
days, as previously described.19 Rats in the sham group were 
injected with saline (30 µL). Both MIA and sham rats were 
injected with saline (30 µL) in the tibiotarsal joint of the right 
hind paw at 7, 14, and 21 days after MIA/saline injection. 
Rats in the MIA-HA group were injected with HA (30 µL) 
into the tibiotarsal joint of the right hind paw at 7, 14, and 
21 days after MIA injection.
ankle measurement
At all of the indicated time points, we examined differences 
in the transverse and anteroposterior diameter and range of 
motion (ROM) in the affected and unaffected ankles. Ankle 
diameters were measured using digital calipers at the ankle 
neutral position. Each diameter was measured three times 
at each time point.
ROM of each ankle was measured using a protractor. The 
dorsiflexion angle was subtracted from the plantarflexion 
angle, and the arcs of the right and left ankles were calculated. 
The differences between right and left ankle arcs were then 
compared at all time points.
Walking stride length on an acrylic board (7×150×12 
cm) was also measured at all time points. Stride length was 
measured three times using an iPad Air 2 device (Apple, 
Cupertino, CA, USA), and the average difference between 
the affected and unaffected sides was calculated.
Behavioral analysis
Pain-related behavior was assessed by observing the mechan-
ical and thermal hind paw withdrawal responses before 
injection (pre-MIA/saline) and at 7, 14, 21, and 28 days after 
MIA/saline injection. For mechanical allodynia assessment 
of mechanical withdrawal responses, each rat was placed in 
a Plexiglas chamber (18×25×18 cm; IITC Life Science Inc., 
Woodland Hills, CA, USA) above a wire mesh floor, allowing 
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Efficacy of hyaluronic acid in ankle osteoarthritis pain
Next, mechanical withdrawal responses to von Frey filament 
stimuli (2 and 4 g, Semmes Weinstein Monofilaments; North 
Coast Medical Inc., San Jose, CA, USA) were evaluated at 
the time points mentioned above, as previously described.20,21 
Both the right and left hind paws were stimulated 30 times 
with a minimum interval of 10 minutes between sessions. 
The mechanical withdrawal frequency was recorded by 
subtracting the number of responses on the left side from 
that on the right side.
The thermal paw withdrawal response was measured 
by using a radiant heat source (Tail Flick Analgesia 
Meter; IITC Life Science Inc.) to evaluate hyperalgesia 
at all of the time points stated above. Each rat was placed 
in a Plexiglas chamber on a glass platform and allowed 
to acclimatize for at least 20 minutes before the test. The 
thermal withdrawal response was evaluated as the latency 
of hind paw withdrawal in response to thermal stimula-
tion delivered using a radiant source that had been moved 
beneath the portion of the hind paw that was flushed against 
the glass. Each hind paw was tested five times, and the 
mean withdrawal latency was calculated. The thermal paw 
withdrawal latency was defined as asymmetrical left–right 
latency.
histologic assessments
Rats were sacrificed 28 days after MIA/saline injection for 
histologic assessments. The right ankle joints were dis-
sected, fixed in 10% formalin, and embedded in paraffin. 
Sections were prepared and stained with H&E or safranin-O 
fast green and observed under a microscope. We observed 
the histopathologic changes on the distal medial/lateral 
tibial surface and the proximal medial/lateral talus surface 
of the right hind paw tibiotarsal joint. The Osteoarthritis 
Research Society International (OARSI) OA cartilage 
histopathology assessment system was used to assess the 
severity of articular cartilage damage.22 In this system, the 
grade of damage from 0 (normal) to 6 (severe) is defined 
as the progression of OA into the cartilage, and the stage 
of damage is defined as the horizontal extent of cartilage 
involvement from 0 (normal) to 4 (large). The final score 
is the combined value of grade and stage (score range of 
0–24).
statistical analysis
All numerical data are expressed as means and standard 
errors of the means. All data were analyzed using one-way 
repeated measures ANOVA and the Tukey–Kramer test for 
comparisons among the three experimental groups. P<0.05 
was considered statistically significant.
Results
changes in ankle appearance
When compared with sham rats, MIA and MIA-HA rats 
had significant swelling in the anteroposterior and trans-
verse diameters of the right ankle at all four post-injection 
time points (Figure 1). No significant differences in ankle 
anteroposterior or transverse diameter were observed between 
MIA and MIA-HA rats at any post-injection time point. 
Therefore, HA injection produced no significant effects on 
ankle appearance.
Compared with the sham rats, a reduction in ROM was 
observed from 7 days after MIA/saline injection in both 
MIA and MIA-HA rats (Figure 2). In the sham rats, ROM 
was similar on both sides. Further, the ROM on the affected 
side was similar in both MIA-HA and MIA rats, indicating 
that HA did not improve ankle ROM.
evaluation of pain-related behavior
The MIA and MIA-HA rats exhibited a significantly shorter 
walking stride than the sham rats at 7 days after MIA injection 
(Figure 3). However, only the MIA rats had a significantly 
shorter stride than the sham rats at 14, 21, and 28 days after 
MIA/saline injection. Further, the MIA rats also had a signifi-
cantly shorter stride than the MIA-HA rats at 14, 21, and 28 
days after MIA injection. No differences between MIA-HA 
rats and sham rats were observed at 14, 21, and 28 days after 
injection. HA injections improved the stride length 14 days 
after MIA injection.
Compared with that in sham rats, the mechanical 
response frequency increased in both the MIA and MIA-
HA rats at 7 days after MIA/saline injection. We observed 
a significant increase in the response frequency of the 
ipsilateral hind paw to the 2 and 4 g filament in only MIA 
rats at 14, 21, and 28 days after MIA injection (Figure 4). 
Allodynia did not occur 14 days after MIA injection or 
thereafter in the MIA-HA rats.
Further, we observed significantly shorter thermal 
latency in the MIA rat hind paws than in the sham and 
MIA-HA rat hind paws 14 days after MIA/saline injec-
tion (Figure 5). In the MIA rats, hyperalgesia was seen 
14 days after MIA injection, while MIA-HA rats did not 
exhibit hyperalgesia at any of the four post-injection time 
points.
histologic changes
We observed histologic changes such as chondrocyte dis-
organization, erosion, surface fibrillation, and subchondral 
bone exposure in both MIA and MIA-HA rats 28 days after 
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cartilage denaturation were observed beginning 7 days 
after MIA injection (Figure 6). These changes progressed 
further 14 days after MIA injection. Collapse of the talus 
was observed 21 days after MIA injection. Histologic 
denaturation including chondrocyte disorganization, ero-
sion, cartilage surface fibrillation, and subchondral bone 
exposure was observed in both the MIA and MIA-HA rats 
28 days after MIA injection. However, the joint space was 
better preserved and cartilage denaturation was milder in 
the MIA-HA rats than in the MIA rats.
To evaluate these changes quantitatively, we utilized 
the OARSI OA cartilage histopathology assessment system 
(Table 1). MIA rats had a significantly higher OARSI grade 
than MIA-HA and sham rats at all sites. MIA-HA rats showed 
a significantly higher OARSI grade than sham rats in only 
the medial tibia. Both the MIA and MIA-HA rats had sig-
Figure 1 changes in ankle swelling.
Notes: The anteroposterior (A) and transverse (B) diameters of the ankle were elevated in the MIA group. When comparing MIA and MIA-HA rats, no significant differences 
in anteroposterior or transverse ankle diameter were observed at any post-injection time point. Data are shown as the mean ± standard errors of the mean. *P<0.05: 
significant difference compared to sham rats.
Abbreviations: ha, hyaluronic acid; Mia, monoiodoacetate.
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Efficacy of hyaluronic acid in ankle osteoarthritis pain
Figure 2 The range of motion of the ankle (arc of the affected side).
Notes: We subtracted the dorsiflexion angle from the plantarflexion angle and calculated the arc on the right and left ankles. Differences between right and left ankle arcs 
were then compared. No significant differences between MIA and MIA-HA groups were observed. *P<0.05: significant difference compared to sham rats.







































Figure 3 change of stride length.
Notes: Compared with sham rats, MIA and MIA-HA rats exhibited a significantly 
shorter walking stride on the seventh day following Mia/saline injection. Only Mia 
rats had a significantly shorter stride than sham rats at 14, 21, and 28 days after MIA/
saline injection. MIA rats also had a significantly shorter stride than MIA-HA rats at 
14, 21, and 28 days after Mia injection. *P<0.05: significant difference compared to 
sham rats. #P<0.05: significant difference compared to MIA-HA rats.
Abbreviations: ha, hyaluronic acid; Mia, monoiodoacetate.























nificantly higher OARSI stages than sham rats at all sites. 
However, no significant difference in OARSI stage was found 
between MIA and MIA-HA rats at any site.
The OARSI score is the final combined value of grade 
and stage. MIA rats showed a significantly higher OARSI 
score than MIA-HA and sham rats at all sites. There was 
no significant difference between MIA-HA and sham rats 
at any site.
Discussion
OA is one of the most prevalent and debilitating joint diseases 
and is associated with reduced quality of life and increased 
health care costs. OA causes the loss of articular cartilage, 
damage to all joint structures including adjacent support-
ing connective tissue elements, subchondral bone changes, 
varying degrees of osteophyte formation, and synovitis.1 
Recommendations for the management of OA, especially 
knee OA, have been issued by the European League Against 
Rheumatism, the European Society for Clinical and Eco-
nomic Aspects of Osteoporosis and Osteoarthritis, the Ameri-
can College of Rheumatology, and the OARSI.23–28 Current 
treatment options include simple analgesics, NSAIDs, intra-
articular HA or corticosteroid injections, orthotics, physical 
therapy, and surgical interventions. In case of contraindica-
tions to NSAIDs, severe symptoms, or if the patient is still 
symptomatic despite NSAID use, intra-articular treatment 
may be applied.29 Intra-articular HA injections are relatively 
safe, and compared with intra-articular corticosteroids, HA 
induces long-lasting pain control.14 In a meta-analysis, Chang 
et al reported that, compared to their pretreatment condition, 
intra-articular HA administration significantly reduced pain 
for patients with ankle OA.30 Although increased HA injec-
tion volume does not result in additional pain relief, a positive 
relationship between total number of HA injection doses 
and effect size was observed, and the use of multiple doses 
is likely more beneficial than a single injection. Witteveen 
et al reported that three weekly injections of HA provided 
greater pain relief than a single injection.31 Minimal relations 
existed between HA MW and treatment response. High-MW 
HA has a higher viscosity and is eliminated from the joints 
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We previously reported a rat model of MIA-induced ankle 
OA.19 This model is useful in studying ankle OA because 
cartilage degeneration is induced efficiently and the model 
has high reproducibility. The present study demonstrated that 
intra-articular injection of HA suppressed hypersensitivity, 
thermal hyperalgesia, and stride length in a rat model of 
MIA-induced ankle OA. Progression of joint denaturation 
was also suppressed. On the other hand, intra-articular HA 
injection did not affect ankle swelling or ankle ROM.
Balazs and Denlinger reported that HA can modulate 
the early inflammatory response and has anti-inflammatory 
effects.12 The structural breakdown of proteoglycans (PGs) 
and collagen is considered to be the result of increased chon-
drocyte catabolic activity.33 IL-1β is a cytokine involved in 
cartilage degradation. IL-1β causes chondrocytes to secrete 
neutral matix metalloproteinases (MMPs) and nitric oxide 
(NO). NO is a highly reactive and cytotoxic free radical that 
has been implicated in tissue injury, inhibition of matrix 
synthesis, and activation of MMPs. HA protects chondrocytes 
from the effects of IL-1β, decreases NO levels, and facilitates 
the restoration of PG.34–36
In the present study, no improvement in ankle swelling 
was observed. This may be due to chronic MIA-induced 
inflammation. In addition, there is a possibility that ROM 
improvements were not seen because ankle swelling per-
sisted. On the other hand, stride length was improved in HA 
Figure 5 assessment of thermal hyperalgesia.
Notes: in Mia rats, hyperalgesia was seen 14 days after Mia injection. Mia-ha 
rats did not exhibit hyperalgesia at any post-injection time point. *P<0.05: significant 
difference compared to sham rats. #P<0.05: significant difference compared to MIA-
ha rats.
Abbreviations: ha, hyaluronic acid; Mia, monoiodoacetate.
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Figure 4 assessment of mechanical hypersensitivity (allodynia).
Notes: A significant increase in the response frequency of the ipsilateral hind paw was only observed in MIA rats at 14, 21, and 28 days after MIA injection. (A) von Frey 2 
g and (B) 4 g filaments. *P<0.05: significant difference compared to sham rats. #P<0.05: significant difference compared to MIA-HA rats.
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Efficacy of hyaluronic acid in ankle osteoarthritis pain
rats, which we suspect occurred because intra-articular HA 
injections had an effect on pain relief. Peripheral sensitization 
of afferent nerve stimulus is typically seen after tissue damage 
or flare responses due to marked nociceptive neuropeptide 
production. This then results in increased sensitivity to heat 
and touch stimuli, referred to as primary hyperalgesia or 
primary allodynia if the stimulus was not painful prior to 
injury.37 Central sensitization represents an enhancement in 
the function of neurons and circuits in nociceptive pathways 
caused by increases in membrane excitability and synaptic 
efficacy. Central sensitization is also a manifestation of the 
remarkable plasticity of the somatosensory nervous system in 
response to activity, inflammation, and neural injury.38 There-
fore, central sensitization produces pain hypersensitivity by 
changing the sensory response elicited by normal inputs, 
including those that usually evoke innocuous sensations. We 
used a von Frey test to evaluate allodynia and a plantar test 
for hyperalgesia.39,40 Thakur et al reported increased central 
sensitization and referred pain in a rat model of knee OA.41 
They suggested that the existence of central changes in OA 
resembles neuropathic pain. Zhang et al reported that OA 







Figure 6 histology of ankle joints.
Notes: (A–F) histology of ankle joints obtained from each rat. (A) Mia rat 7 days after injection. (B) Mia rat 14 days after injection. (C) Mia rat 21 days after injection. 
(D) Mia rat 28 days after injection. (E) Mia-ha rat 28 days after injection. (F) sham rat 28 days after injection.
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Ikeuchi et al examined the effect of intra-articular HA 
injection on pain in a rat model of knee OA. They reported 
that intra-articular HA injection reduced OA severity, 
decreased paw mechanical hyperalgesia, and attenuated OA-
associated upregulation of calcitonin gene-related peptide 
(CGRP). However, no studies have investigated the effects 
of HA on pain relief in a model of ankle OA.42 In our study, 
significant mechanical hypersensitivity (ie, allodynia) was 
observed in the MIA rats, but not in the MIA-HA rats, 14 
days after MIA injection. Similarly, we observed significant 
thermal hyperalgesia in the MIA rats, but not in the MIA-
HA rats 14 days after MIA injection. These observations 
suggested that HA suppressed peripheral and/or central 
sensitization. We speculated that nociceptive pain was alle-
viated due to intra-articular HA injection. Examination of 
biochemical and neurophysiological processes may provide 
an improved understanding of the pathogenesis of pain asso-
ciated with ankle OA. The increases in c-Fos expression and 
the unregulated glutamate receptor subunit expression in the 
dorsal root ganglion and dorsal horn neurons are known to 
indicate the occurrence of peripheral and/or central sensiti-
zation.43,44 Microglia and astrocyte activation in the dorsal 
horn neurons produces initiators and regulators of central 
sensitization pain including brain-derived neurotrophic fac-
tor and proinflammatory cytokines IL-1β, tumor necrosis 
factor-α, and IL-6, which modulate chronic pain.45 Further 
study is needed to assess pain associated with ankle OA to 
reflect a dominance of nociceptive, peripheral, and central 
pain mechanisms, respectively.
It is possible that allodynia is alleviated due to sup-
pression of cartilage degeneration by intra-articular HA 
administration. Due to its resultant pain relief and joint 
functional improvements, viscosupplementation is used 
to treat OA worldwide.46 HA is potentially effective as a 
chondroprotective agent due to alterations in catabolic and 
anabolic balance of the joint.47 Due to its poor oral bioavail-
ability and risk of systemic toxicity, HA is a candidate for 
intra-articular use.9 Preliminary observations and evalua-
tions of conventional approaches, such as intra-articular 
viscosupplemental administration of HA, have shown some 
convincing benefits and anti-inflammatory potential in both 
animal and human subjects.48–51
To the best of our knowledge, no study has investigated 
the effect of intra-articular HA administration in an ankle OA 
model. The articular cartilage of the ankle is more resistant 
to degeneration than that of the knee.52 Some studies have 
revealed several differences between the knee and ankle 
joint, including their structure, biomechanical properties, and 
chondrocyte phenotype. Biomechanical research has revealed 
that ankle cartilage has higher dynamic stiffness than knee 
cartilage.53 Moreover, each layer of articular cartilage in the 
ankle is thinner than that in the knee.54 In explant culture, 
ankle cartilage has been shown to be less responsive to cata-
bolic stimulation than knee cartilage.55
In the present study, there was no signif icant 
difference in OARSI stage between MIA and MIA-HA rats; 
however, OARSI grade was significantly higher in MIA rats. 
Even in OARSI score, MIA rats displayed severe cartilage 
degeneration, but MIA-HA rats displayed an inhibition of 
degeneration. Based on these findings, we conclude that HA 
exerted a chondroprotective effect in a rat model of MIA-
induced ankle OA. We infer that in addition to cartilage 
degeneration, sensitization was also suppressed by the anti-
inflammatory and viscosupplemental effects of HA.
Limitations
Limitations of our study should be considered. A major limi-
tation is that we did not estimate the effects of different HA 
MWs and the frequency of administration. In addition, we 
did not immunohistochemically investigate the expression of 
pain-related receptors in the dorsal root ganglion and spinal 
cord. There are currently no immunohistochemical reports 
of this nature in a rat model of MIA-induced ankle OA. As 
such, further study is needed to assess pain associated with 
ankle OA to reflect a dominance of nociceptive, peripheral, 
and central pain mechanisms, respectively.
Table 1 histopathologic evaluation of safranin-O fast green-
stained cartilage by OaRsi cartilage Oa histopathology grading 
system
Area MIA MIA-HA Sham
lateral tibia
grade 5.0 (0.3)*,# 1.6 (0.2) 1.0 (0)
stage 3.6 0.4)* 2.6 (0.2)* 0 (0)
score 18.0 (2.4)*,# 4.2 (0.8) 0 (0)
Medial tibia
grade 4.6 (0.2)*,# 1.8 (0.2)* 1.0 (0)
stage 3.6 (0.4)* 2.8 (0.4)* 0 (0)
score 16.4 (1.8)*,# 5.2 (1.0)* 0 (0)
lateral talus
grade 5.0 (0.3)*,# 1.8 (0.5) 1.0 (0)
stage 3.4 (0.2)* 2.2 (0.6)* 0 (0)
score 17.2 (2.1)*,# 5.0 (2.3) 0 (0)
Medial talus
grade 4.6 (0.2)*,# 2.2 (0.6) 1.6 (0.2)
stage 3.8 (0.2)* 2.6 (0.2)* 1.2 (0.5)
score 17.4 (1.1)*,# 5.0 (2.3) 2.4 (1.0)
Notes: The OaRsi score is the combined value of grade and stage (score range 
0–24). Data represent the mean (standard error of the mean) for each group. 
*P<0.05: significant difference compared to sham rats. #P<0.05: significant difference 
compared to Mia-ha rats.
Abbreviations: ha, hyaluronic acid; Mia, monoiodoacetate; Oa, osteoarthritis; 
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Efficacy of hyaluronic acid in ankle osteoarthritis pain
Conclusion
The present study established the efficacy of a novel strategy, 
the intra-articular injection of HA in the ankle joint, in a rat 
model of MIA-induced ankle OA. We found that HA sup-
pressed the pain-related behaviors associated with peripheral 
sensitization and/or central sensitization. Additionally, HA 
exerted a chondroprotective effect and inhibited the progres-
sion of ankle OA. Further studies are warranted to explore this 
strategy and identify molecules that alter pain transmission 
in the nervous system.
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